The investigational therapy, ifinatamab deruxtecan, is a potential first-in-class B7-H3 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and jointly developed with Merck
Exclusive distribution pact with Amcor broadens access to Parafilm M sealing solutions for laboratories, horticulture and industrial users
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
Move amid evidence of widespread reporting gaps
CRDMO plans to add 800–1,000 women across scientific and leadership roles over three years
The programme features headline data from pivotal Phase III trials, including PREVAIL in gMG, KOMET in NF1-PN, and CHAMPION-NMOSD, alongside real-world evidence supporting established therapies
Backed by funding from an NIHR Doctoral Award, the guidance is focused on spotting abdominal tumours
A major push to sharpen the future of cancer treatment is underway
Scientists at the forum warned of an increasingly volatile health landscape
The study’s multi-technology design is intended to improve reproducibility, strengthen regulatory-grade evidence generation
Subscribe To Our Newsletter & Stay Updated
